•   
  • $0.00 USD
    0

Horizon to provide human genomic reference standards to assure quality and performance of Transgenomic’s Multiplexed ICE COLD-PCR kits

CAMBRIDGE, UK, and OMAHA, NE, USA  (April, 23, 2015)Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, and Transgenomic, Inc. (NASDAQ: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology and inherited diseases through advanced diagnostic tests and clinical and research services, today announced a new Original Equipment Manufacture (OEM) agreement to incorporate Horizon’s human genomic reference standards, produced by Horizon’s Diagnostics division, into Transgenomic’s Multiplexed ICE COLD-PCRTM (MX-ICP) kits for use in research and clinical applications. Further details of the agreement were not disclosed.

Read More

Why should laboratories be using Genomic DNA rather than Plasmids and what are the advantages?

In molecular biology, plasmid DNA has proved to be a vital tool for many applications.  However, when developing or validating assays which will ultimately measure human genomic DNA samples, plasmid DNA may not be an ideal control sample.

Read More

Hosted by CAP Today April-28-2015

Veterans of the industry (Chris Corless, MD PhD & Josh Deigan, PhD) will be presenting 4 key topics on molecular quality control. This webinar will empower you to better understand quality control in the workplace.

Read More

Formalin-Fixed, Paraffin Embedded Sections on Slide - Routinely monitor your Assay

The availability of genetically defined reference materials offers an industry standard for development and quality control of IHC assays, directly improving the accuracy and reproducibility. IHC HDx™ Reference Standards provide laboratories with a consistent source of positive and negative reference material on one slide.

Read More

At Horizon Diagnostics, we are constantly looking to develop easier and simpler ways of doing business.

To save you time, we've upgraded our website and ordering system to make it much more convenient to place orders. In doing so, and to comply with data protection acts, you will be required to register for a new account to order online. As a pre-existing account holder we encourage you to sign up for a new account at www.horizondx.com.

Read More

18/04/2015 | Philadelphia, PA, USA

The AACR Annual Meeting 2015 will highlight the latest, most exciting discoveries in every area of cancer research and will provide a unique opportunity for investigators from all over the world to meet, interact, and share their insights.

Read More
Posted in Events

Horizon’s Reference Materials chosen by ArcherDX to validate its FusionPlex test for non-small cell lung cancer markers

Cambridge, UK, and Boulder, CO, USA, 23rd March 2015: Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, and ArcherDX, Inc., a leader in Next Generation Sequencing (NGS) fusion detection, today announced they have signed an Original Equipment Manufacture (OEM) agreement that will see Horizon’s Reference Materials supplied as a standalone product alongside ArcherDX’s ArcherFusionPlex™ to aid customer validation of its ALK fusion assay kits.

Read More
Horizon Diagnostics has released new catalog numbers for the following products. These will replace all pre-existing catalog numbers as of the 25th February 2015:Read More
In the past FDA has retained its enforcement discretion on Laboratory Developed Tests (LDTs), the situation is starting to change with the FDA moving to regulate LDT manufacture and listing. An LDT is an IVD that was historically designed, manufactured, verified and validated for use within a single laboratory. The move to regulate comes from changes in the status of LDTs for a number of key reasons.
Read More

In a first, an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor IRESSA® (gefitinib) has received European label indication recommending the use of cell-free DNA from a blood sample when obtaining a tumour sample from a patient is not possible. This label change is based on the results of a collaboration between AstraZeneca and Qiagen.

IRESSA acts by blocking the transmission of signals involved in the growth and spread of tumors and is approved in 90 countries for the treatment of adult patients with locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC).

Read More

1-10 of 15

Page:
  1. 1
  2. 2

Our Products